It will be started in a week, i assume it's too late for the hcg?
Don't waste your money...
As for hCG, I don't understand why anyone would want to create another level of suppression in their HPTA? There is really no use for hCG, it desensitizes leydig cells in your testes to Leutinizing hormone so that when you eventually cease using hCG it takes a while for your testes to become sensitive to your own body's natural LH, thus prolonging your recovery. The use of hCG in males is limited to increasing fertility in HRT such that guys have enough viable sperm for their partners to conceive. When you are "shut down" your testes actually become more sensitive to LH due to receptor up-regulation. All that hCG will do is prolong your recovery.
Enclomiphene citrate increased testosterone and sperm counts. Concomitant changes in LH and FSH suggest normalization of endogenous testosterone production and restoration of sperm counts through the hypothalamic-pituitary-testicular axis.
http://www.ncbi.nlm.nih.gov/pubmed/23530575
Low dose clomiphene citrate is effective in elevating serum testosterone levels and improving the testosterone/estradiol ratio in men with hypogonadism. This therapy represents an alternative to testosterone therapy by stimulating the endogenous androgen production pathway.
http://www.ncbi.nlm.nih.gov/pubmed/16422830
Triptorelin depot stimulation test for central precocious puberty.
Strich D, Kvatinsky N, Hirsch HJ, Gillis D.
Abstract
BACKGROUND:
Acute gonadotropin responses following depot leuprolide acetate injection are useful for monitoring therapeutic efficacy in central precocious puberty. Similar monitoring of therapy in patients treated with another widely used GnRH agonist, depot triptorelin, has not yet been reported.
OBJECTIVE:
The objective of this study was to test the use of gonadotropin levels after therapeutic injections of depot triptorelin for evaluating efficacy of therapy.
PATIENTS AND METHODS:
Thirty-two patients (29 girls and three boys) were treated with triptorelin depot, 3.75 mg per vial, between 2006 and 2010. Treatment was initiated at 8.27±1.76 years (range, 4.6-11.6 years). Blood was drawn before and at variable times between 30 min and 2 h after injections. Clinical tests were retrospectively collected. Results: After the first injection, the 60-min mean luteinizing hormone (LH) level was 21.6.1±18.0 IU/L and the follicle-stimulating hormone (FSH) was 13.5±3.6 IU/L. After subsequent injections, for those who showed clinical suppression, the standard deviations above the mean were 3.6 IU/L for FSH and 2.1 IU/L for LH. The LH levels of two patients who did not suppress sufficiently were at these limits or higher.
CONCLUSIONS:
Sixty-minute postinjection depot triptorelin levels of LH can be successfully used to evaluate the efficacy of treatment with this agent. Limits for suppressed levels have been determined.
http://www.ncbi.nlm.nih.gov/pubmed/23425599